Your browser doesn't support javascript.
loading
Ibrutinib is Effective in Refractory Type II Cryoglobulinemia.
Barot, Shimoli V; Lee, Sarah S; Patel, Bhumika J; Valent, Jason N.
Afiliación
  • Barot SV; Myeloma Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Lee SS; Myeloma Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Patel BJ; Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Valent JN; Myeloma Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Electronic address: valentj3@ccf.org.
Clin Lymphoma Myeloma Leuk ; 19(12): e629-e632, 2019 12.
Article en En | MEDLINE | ID: mdl-31585822
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinas / Crioglobulinemia / Inhibidores de Proteínas Quinasas Tipo de estudio: Etiology_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Clin Lymphoma Myeloma Leuk Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinas / Crioglobulinemia / Inhibidores de Proteínas Quinasas Tipo de estudio: Etiology_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Clin Lymphoma Myeloma Leuk Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article